StreetInsider.com News Articles

Clearmind enrolls first AUD patients in CMND-100 trial

Fri, 11 Sep 2026 08:01:54 -0400

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder in its clinical trial evaluating CMND-100, a psychedelic-based treatment candidate, according to a company statement.

The first two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel. Prior to this enrollment, CMND-100 had only been administered to healthy participants across multiple doses as part of the company's clinical development program.

The trial is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with Alcohol Use Disorder.

"Our enrollment trajectory continues to build positively and treating the first Alcohol Use Disorder patients with CMND-100

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Fri, 11 Sep 2026 08:00:00 -0400

Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the enrollment of the first patients with Alcohol Use Disorder (“AUD”) in its ongoing clinical trial evaluating CMND-100, the Company’s proprietary psychedelic-based treatment candidate for AUD.

The first two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, marking the first time CMND-100 is administered to a patient with AUD. To date, the Company has evaluated

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Fri, 11 Sep 2026 08:00:00 -0400

The first two patients were enrolled at Hadassah Medical Center in Jerusalem, Israel, marking the first time CMND-100 is administered to a patient with AUD. To date, the Company has evaluated

Form 6-K Clearmind Medicine Inc. For: Jul 31

Thu, 10 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260910/27048396.html

Yale approves Clearmind Medicine patient recruitment for CMND-100 trial

Tue, 08 Sep 2026 07:43:15 -0400

Clearmind Medicine Inc. (NASDAQ: CMND) announced that Yale University's Institutional Review Board has approved patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND-100, a compound being studied as a treatment for Alcohol Use Disorder (AUD).

The approval allows Clearmind to expand enrollment at Yale School of Medicine's Department of Psychiatry. Yale joins Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, which are already approved and actively recruiting patients. The Yale site is led by Anahita Bassir Nia, MD, a specialist in psychiatry and addiction medicine.

The multicenter trial is

Yale approves Clearmind Medicine patient recruitment for CMND-100 trial

Tue, 08 Sep 2026 07:43:15 -0400

The multicenter trial is

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

Tue, 08 Sep 2026 07:42:00 -0400

Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced that the Yale University’s IRB has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial evaluating CMND‑100.

This approval advances the multicenter study, titled “A Phase I/II Single and Multiple Dose Tolerability, Safety and Pharmacokinetic Study of CMND‑100 in Healthy Volunteers and Subjects with AUDand directly enables

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

Tue, 08 Sep 2026 07:42:00 -0400

Clearmind Medicine to acquire 51% of EV wireless charging firm

Fri, 04 Sep 2026 07:32:14 -0400

Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biotech company, has signed a definitive agreement to acquire a 51% stake in Charging Robotics, a company that develops wireless charging systems for automated parking facilities and autonomous vehicles, according to a press release.

Under the terms of the deal, Clearmind will pay $2.5 million for the majority stake. In addition, Clearmind will extend a $1.5 million loan to Charging Robotics at an interest rate of 4% per annum. The loan is due on the three-year anniversary of the closing, with an automatic extension if Charging Robotics has not generated sufficient positive cash flow

Clearmind Medicine to acquire 51% of EV wireless charging firm

Fri, 04 Sep 2026 07:32:14 -0400

Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis

Fri, 04 Sep 2026 07:32:00 -0400

Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments where conventional cables and plug-in infrastructure cannot operate.

Vancouver, Canada, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a definitive agreement (“Agreement”) to acquire a 51% stake in Charging Robotics, an intelligent

Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis

Fri, 04 Sep 2026 07:32:00 -0400

Clearmind starts Phase IIa trial of CMND-100 for alcohol disorder

Tue, 01 Sep 2026 07:37:26 -0400

Clearmind Medicine Inc. (Nasdaq: CMND) announced the initiation of Phase IIa of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD), according to a press release issued Sept. 1, 2026.

Six patients have been enrolled to date, with three participants at Tel Aviv Sourasky Medical Center and three at Hadassah Medical Center in Jerusalem. This marks the beginning of the first multiple-dose treatment phase, known as Part C, following the completion of the trial's initial safety phase conducted in healthy volunteers.

The Phase IIa trial is designed to evaluate the safety, tolerability, and preliminary

Clearmind starts Phase IIa trial of CMND-100 for alcohol disorder

Tue, 01 Sep 2026 07:37:26 -0400

The Phase IIa trial is designed to evaluate the safety, tolerability, and preliminary

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Tue, 01 Sep 2026 07:37:00 -0400

Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), announced today the initiation of Phase lla, the next stage of its double-blind, placebo-controlled Phase I/IIa clinical trial evaluating CMND-100 for the treatment of AUD, with six patients enrolled to date. Three participants have been enrolled at Tel Aviv Sourasky Medical Center (TASMC) and three at Hadassah Medical Center in Jerusalem, initiating the first multiple-dose treatment phase of Part C (“phase

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Tue, 01 Sep 2026 07:37:00 -0400

Form 6-K Clearmind Medicine Inc. For: Aug 24

Mon, 24 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26968003.html

Form 6-K Clearmind Medicine Inc. For: Aug 24

Mon, 24 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260824/26968003.html

SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD

Mon, 24 Aug 2026 08:51:51 -0400

SciSparc Ltd. (NASDAQ: SPRC) announced that its subsidiary, NeuroThera Labs Inc. (TSXV: NTLX), and its collaborator Clearmind Medicine Inc. (NASDAQ: CMND) have had a U.S. patent application published covering a combination of MDMA and N-acylethanolamines, such as palmitoylethanolamide (PEA), for potential use in treating post-traumatic stress disorder, anxiety, and eating disorders.

The United States Patent and Trademark Office published the application, which covers embodiments relating to the potential use of PEA in combination with MDMA, including potential effects on therapeutic potency, required dosing, side effects, and therapeutic window.

According to the company's statement, the collaboration between NeuroThera and Clearmind has generated a

SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD

Mon, 24 Aug 2026 08:51:51 -0400

According to the company's statement, the collaboration between NeuroThera and Clearmind has generated a

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation